Atea Pharmaceuticals (AVIR) Receivables - Net (2021 - 2022)
Atea Pharmaceuticals' (AVIR) quarterly Receivables - Net came in at $4.5 million in Q3 2022, down 90.97% quarter-over-quarter from $50.0 million in Q2 2021.
Atea Pharmaceuticals (AVIR) Receivables - Net (2021 - 2022) Analysis & Trends
Atea Pharmaceuticals' Receivables - Net history runs 2 years deep, the most recent figure standing at $4.5 million for Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Atea Pharmaceuticals | 376.19 Mn | 376.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 4.51 Mn |
| Sep 30, 2022 | 4.51 Mn |
| Jun 30, 2021 | 50.00 Mn |
| Jun 30, 2021 | 50.00 Mn |